Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person16
REGENXBIO Inc.
Company
Regen BioPharma Inc
Company
Regenlab USA Inc.
Company
iBio, Inc.
Company
IN8BIO, INC.
Company
REGENEREX PHARMA, INC.
Company
ImageneBio, Inc.
Company
REED'S, INC.
Company
BIOGEN INC.
Company
Reddit, Inc.
Company
Vogenx, Inc.
Company
RESMED INC
Company
Rezera Inc.
Company
GRI Bio, Inc.
Company
REVVITY, INC.
Company
Q32 Bio Inc.
Company
Primary record14
REGENXBIO Inc. filed 8-K
Item 2.02. Results of Operations and Financial Condition. On November 5, 2026, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended Septe
REGENXBIO Inc. filed 4
SEC form 4 filed by REGENXBIO Inc. (CIK 1590877) on 2026-11-03.
REGENXBIO Inc. filed 4
SEC form 4 filed by REGENXBIO Inc. (CIK 1590877) on 2026-11-03.
REGENXBIO Inc. filed 4
SEC form 4 filed by REGENXBIO Inc. (CIK 1590877) on 2026-11-03.
REGENXBIO Inc. filed 4
SEC form 4 filed by REGENXBIO Inc. (CIK 1590877) on 2026-11-03.
REGENXBIO Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 14, 2026, Kenneth T. Mills resigned from the board o
JPMORGAN CHASE & CO filed SCHEDULE 13G
0000019617-26-000350.txt : 20261013 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0000019617 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 09/30/2026 0001590877 REGENXBIO Inc. 75901B107 9804 Medical Center
Sarepta Therapeutics, Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. On September 23, 2026 (the Effective Date ), Sarepta Therapeutics, Inc. (the Company ), Sarepta Therapeutics Three, LLC ( Sarepta Three and, together with the Company
REGENXBIO Inc. filed 8-K
Item 1.01. Entry into a Material Definitive Agreement. On September 23, 2026, REGENXBIO Inc. (the Company ) and The Trustees of the University of Pennsylvania ( UPenn ) entered into a Settlement Agreement (the Settlement
Gossamer Bio, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 16, 2026, upon the recommendation of the Nominatin
REGENXBIO Inc. filed 4
SEC form 4 filed by REGENXBIO Inc. (CIK 1590877) on 2026-09-03.
REGENXBIO Inc. filed 4
SEC form 4 filed by REGENXBIO Inc. (CIK 1590877) on 2026-09-03.
REGENXBIO Inc. filed 4
SEC form 4 filed by REGENXBIO Inc. (CIK 1590877) on 2026-08-27.
REGENXBIO Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 25, 2026, the Board of Directors (the “Board”) of REG